October 2, 2002
AMERIPATH ANNOUNCES STRATEGIC ALLIANCE WITH gMED

Riviera Beach, FL, October 2, 2002 - AmeriPath, Inc. (NASDAQ: PATH), a leading national provider of cancer diagnostics, genomic and related information services, today announced that it has formalized a strategic alliance with gMed. Through this agreement, gMed will automate traditional pathology sample and result delivery through secure electronic transactions. AmeriPath in turn will promote gCare™ nationwide on a non-exclusive basis throughout its national sales network. AmeriPath and gMed will also work together in several research and development projects designed to provide best-practice information and simplify communications at the point of care.

AmeriPath Vice President of Sales, Marketing and Contracting, Bruce Walton, stated, “gMed’s experience and expertise in gastrointestinal electronic medical record and procedure reporting in concert with AmeriPath’s unparalleled excellence in gastrointestinal pathology will ensure our continued success in meeting the needs of our referring physicians.”

“We are looking forward to working closely with AmeriPath.” said Joe Rubinsztain, M.D., CEO of gMed. “They bring innovative ideas, a genuine desire to benefit the client, and an extensive client-base and sales network.”

AmeriPath is a leading national provider of cancer diagnostics, genomics, and related information services. The Company’s extensive diagnostics infrastructure includes the Center for Advanced Diagnostics (CAD), a division of AmeriPath. CAD provides specialized diagnostic testing and information services including Fluorescence In-Situ Hybridization (FISH), Flow Cytometry, DNA Analysis, Polymerase Chain Reaction (PCR), Molecular Genetics, Cytogenetics and HPV Typing. Additionally, AmeriPath provides clinical trial and research development support to firms involved in developing new cancer and genomic diagnostics and therapeutics.

gCare™ is an advanced electronic medical record and procedure reporting application designed for medical specialties. Incorporating the latest Internet technology, gCare combines specialty-specific knowledge with extensive automation to decrease the cost of operation and enhance the level of care and documentation. Based in Weston, Florida, gMed was founded in June 1997 to "enhance well-being in a cost-effective way”. gMed aims to become the de facto standard in specialty based electronic medical records by providing a seamless path to the paperless medical chart. Further information can be obtained at the corporate web site (www.gmedcorp.com) or through E-mail from sales@gmedcorp.com

.............................................................................................

The statements contained in this press release include "forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements - which are sometimes identified by words such as "may", "should", "believe'', "expect'', "anticipate'', "estimate" and similar expressions and which include any financial or operating estimates, forecasts or projections - are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company's control. These risks and uncertainties could cause actual results to differ materially from results anticipated by forward-looking statements. These risks and uncertainties include: the extent of success of the Company's operating initiatives and growth strategies; ability to manage growth; access to capital on satisfactory terms; general economic conditions; terrorism or an escalation of hostilities or war; competition and changes in competitive factors; federal and state healthcare regulation (and compliance); reimbursement rates under government and third party healthcare programs and the payments received under such programs; changes in coding; changes in technology; dependence upon pathologists and customer contracts; the ability to attract, motivate, and retain pathologists; labor, technology and insurance costs; professional liability claims; marketing and promotional efforts; the availability of pathology practices in appropriate locations that the Company is able to acquire on suitable terms or develop; and the successful completion and integration of acquisitions (and achievement of planned or expected synergies). The forward-looking statements in this press release are made as of the date hereof based on management's current beliefs and expectations, and the Company undertakes no obligation to update or revise any such statements. Further information regarding risks, uncertainties and other factors that could affect the Company's financial or operating results or that could cause actual results to differ materially from those expected, estimated or anticipated are included in the Company's reports filed with the SEC.